Frontiers in Pharmacology (Dec 2020)

Simulation Training to Improve Informed Consent and Pharmacokinetic/Pharmacodynamic Sampling in Pediatric Trials

  • Bjoern B. Burckhardt,
  • Agnes Maria Ciplea,
  • Anna Laven,
  • Anna Laven,
  • László Ablonczy,
  • Ingrid Klingmann,
  • Stephanie Läer,
  • Karl Kleine,
  • Michiel Dalinghaus,
  • Milan Đukić,
  • Johannes M. P. J. Breur,
  • Marijke van der Meulen,
  • Vanessa Swoboda,
  • Holger Schwender,
  • Florian B. Lagler

DOI
https://doi.org/10.3389/fphar.2020.603042
Journal volume & issue
Vol. 11

Abstract

Read online

Background: Pediatric trials to add missing data for evidence-based pharmacotherapy are still scarce. A tailored training concept appears to be a promising tool to cope with critical and complex situations before enrolling the very first patient and subsequently to ensure high-quality study conduct. The aim was to facilitate study success by optimizing the preparedness of the study staff shift.Method: An interdisciplinary faculty developed a simulation training focusing on the communication within the informed consent procedure and the conduct of the complex pharmacokinetic/pharmacodynamic (PK/PD) sampling within a simulation facility. Scenarios were video-debriefed by an audio-video system and manikins with artificial blood simulating patients were used. The training was evaluated by participants' self-assessment before and during trial recruitment.Results: The simulation training identified different optimization potentials for improved informed consent process and study conduct. It facilitated the reduction of avoidable errors, especially in the early phase of a clinical study. The knowledge gained through the intervention was used to train the study teams, improve the team composition and optimize the on-ward setting for the FP-7 funded “LENA” project (grant agreement no. 602295). Self-perceived ability to communicate core elements of the trial as well as its correct performance of sample preparation increased significantly (mean, 95% CI, p ≤ 0.0001) from 3 (2.5–3.5) to four points (4.0–4.5), and from 2 (1.5–2.5) to five points (4.0–5.0).Conclusion: An innovative training concept to optimize the informed consent process and study conduct was successfully developed and enabled high-quality conduct of the pediatric trials as of the very first patient visit.

Keywords